Featured Articles
Analysis
What Oregon’s Measure 109 Means for Hopeful Entrepreneurs and Investors
While entrepreneurs and investors are likely to see Oregon’s Measure 109 as a chance to capitalize on new business opportunities and investments, it’s worth highlighting that this new law is unlikely to lead to a psilocybin gold rush.
Analysis
Novamind Goes Public and Carves Foothold In the Psychedelic Industry With a Unique Strategy in Mind
“The standard of care in mental health is broken and has been for decades.” We were speaking with Yaron Conforti, the CEO and Director of Novamind about the catalyst that led to the creation of the company which is going public today, January 5th 2021. Yaron explained that mental health has been in crisis mode […]
Press
PsyBio Therapeutics Corp. Begins Trading on the TSX Venture Exchange
PsyBio Therapeutics Corp. announced that the company will commence trading on the TSX Venture Exchange under the ticker…
Press
PharmaDrug Files For FDA Orphan Drug Designation For DMT
PharmaDrug Inc. announced it has expanded its psychedelic pharmaceutical program with the filing of an application with the…
Press
NeonMind Purchases Synthetic Psilocybin from Psygen Labs Human Clinical Trial
NeonMind Biosciences Inc. announced that it has purchased an initial order of GMP grade psilocybin from Psygen Labs…
Press
PharmaTher Announces Research Collaboration for Novel Microneedle Delivery of Psychedelic Pharmaceuticals
PharmaTher Inc. announced that they have entered into a sponsored research agreement with the Terasaki Institute to develop…
Track the entire psychedelic market using the only index that covers the entire psychedelics marketplace.
Explore the IndexAll Articles
- All
- Analysis
- Interviews
- Press
